Business Context and Reporting Period
This Form 8-K was filed by Heatwurx, Inc. (not Processa Pharmaceuticals, Inc.) on August 30, 2013, reporting an event that occurred on the same date. The company is incorporated in Delaware and headquartered in Greenwood Village, Colorado.
Key Financial Metrics
The filing details a private equity offering rather than operational financial results. Key transaction metrics include:
- Gross Proceeds: $2,182,944
- Units Sold: 727,648 out of an authorized 1,500,000
- Price per Unit: $3.00
- Transaction Costs: $84,233 paid in commissions to selling agents
- Investor Composition: 40 accredited investors and 4 sophisticated non-accredited investors
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the completion of an unregistered sale of equity securities under Section 4(a)(2) and Rule 506(b) of the Securities Act. The company issued Series D Preferred Stock and warrants to raise capital, resulting in an increase in equity and cash assets.
Guidance, Outlook, and Terms
The filing outlines the specific terms of the Series D Preferred Stock and associated warrants:
- Structure: Each unit consists of one Series D Share and one-half warrant.
- Warrant Exercise Price: $3.00 per share.
- Conversion Terms: Series D Shares are convertible into common stock at the holder's option or at the company's option if the common stock trades at or above $4.50 per share for ten consecutive trading days.
- Restrictions: Securities are unregistered and subject to restrictive legends; they cannot be resold in the U.S. absent registration or an exemption.
The filing does not contain management commentary on future outlook, risks, or contingencies beyond the standard disclosure of the unregistered nature of the offering.
Investor Verification Checklist
- Verify the actual identity of the registrant (Heatwurx, Inc.) versus the metadata label (Processa Pharmaceuticals, Inc.).
- Confirm the conversion trigger price of $4.50 for the Series D Preferred Stock.
- Review the net proceeds after deducting the $84,233 in commissions.
- Check for subsequent filings regarding the registration status of these securities for future resale.